News - Merck & Co, Bristol-Myers Squibb


Popular Filters

Physicians views on EGFR wild-type/untested NSCLC treatment

Physicians views on EGFR wild-type/untested NSCLC treatment


According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential…

AstraZenecaBiotechnologyBristol-Myers SquibbEuropeHealthcareMarkets & MarketingMerck & ConivolumabOncologyOno PharmaceuticalpembrolizumabselumetinibUSA

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market


Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020


Having achieved the biggest drug launch to date by generating an astonishing $2.3 billion in its first…

AbbVieAnti-viralsBayerBristol-Myers SquibbCardio-vascularDiabetesGilead SciencesHumiraJanuviaLantusMarkets & MarketingMerck & ConivolumabPharmaceuticalSanofiSovaldiXarelto

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP


Multinational drugmakers might be crying themselves hoarse that India does not protect innovation - that…

Asia-PacificBristol-Myers SquibbFinancialGlaxoSmithKlineIndiaMerck & CoMergers & AcquisitionsMylan LaboratoriesPatentsPharmaceuticalSanofi

Growth drivers for China's type 2 diabetes market


The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs


Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Melanoma market set to grow to more than $2.8 billion by 2021


The branded melanoma drug market is set to grow to more than $2.8 billion across the USA and major European…

Bristol-Myers SquibblambrolizumabMarkets & MarketingMerck & CoOncologyPharmaceuticalYervoy

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon


US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds


People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those…

Bristol-Myers SquibbByettaDiabetesJanuviaMerck & CoPharmaceuticalResearch

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021


The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Amylin said to be attracting several Big Pharma suitors


US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

UK NICE issues final guidance for Tasigna, Glivec, Sprycel, Victrelis and Incivo


In final guidance issued this morning, UK drugs watchdog the National Institute for Health and Clinical…

Anti-viralsBristol-Myers SquibbEuropeGlivecIncivoJanssen-CilagJohnson & JohnsonMerck & CoNovartisOncologyPharmaceuticalPricingRegulationSprycelTasignaVictrelis

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis


In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

UK’s NICE recommends Merck & Co’s Simponi but not B-MS’s Orencia


There was mixed news for US drug majors Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) this…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeMerck & CoOrenciaPharmaceuticalPricingRegulationSimponi Injection

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top